Clinical trials: Relapsed
CAR, Acute Myeloid Leukemia
TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia
This is a clinical study of TAA6 cell injection in the treatment of patients with relapsed / refractory Acute Myeloid Leukemia .
- Trial name
- NCT04692948
- Testing
- Chimeric antigen receptor T cells (car-t)
- Where
- China
- Volunteers
- 5 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Multiple Myeloma, Non-Hodgkin Lymphoma
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This is a Phase I open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab administered as a single agent or in combination with…
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma
- Trial name
- NCT04045028
- Testing
- Tiragolumab, Daratumumab/rHuPH20, Rituximab
- Where
- 14 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Genentech, Inc.
Glioblastoma Multiforme
Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma
This study seeks to (i) determine the safe dose of CYT997 when given in combination with carboplatin in patients with relapsed glioblastoma multiforme (glioma) and (ii) to determine whether the combination of CYT997 with…
- Trial name
- NCT00650949
- Testing
- CYT997, Carboplatin
- Where
- 4 sites in Australia
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
The purpose of this study is to determine the efficacy and safety of a fixed-dose, daily regimen of orally administered PCI-32765 combined with ofatumumab in subjects with relapsed/refractory CLL/SLL and related diseases
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocyctic Leukemia, Richter's Transformation
- Trial name
- PCYC-1109-CA (NCT01217749)
- Testing
- PCI-32765, ofatumumab
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Pharmacyclics LLC.
Multiple Sclerosis
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Study assessing cognitive function and physical activity in people with relapsing remitting multiple sclerosis.
- Trial name
- CogniPlus (NCT01491100)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 17 sites in Albania, Algeria and 15 more
- Volunteers
- 1,085 people
- Sponsor
- Bayer
Relapsing Remitting Multiple Sclerosis
A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
Teva is developing laquinimod tablets as a new oral treatment for MS. Laquinimod has immunomodulating properties. In a previous clinical study laquinimod showed evidence of biological activity by reducing the number of acute…
- Trial name
- NCT00349193
- Testing
- laquinimod 0.3, laquinimod 0.6
- Volunteers
- 306 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Myeloma
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916
This study will assess the safety, pharmacokinetic (PK), pharmacodynamic (PD) and the therapeutic potential of GSK2857916 in subjects with multiple myeloma (MM) and lymphomas that express B cell maturation antigen (BCMA).
- Trial name
- NCT02064387
- Testing
- GSK2857916
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
The purpose of this study is to assess the safety and tolerability of mRNA-4106 monotherapy and of mRNA-4200 in combination with checkpoint inhibitor therapy in participants with solid tumors.
- Trial name
- NCT06880549
- Testing
- mRNA-4106, Pembrolizumab, mRNA-4200
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- ModernaTX, Inc.
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with R/R AML irrespective the FLT3 status.
- Trial name
- NCT02626338
- Testing
- Crenolanib, Mitoxantrone, Cytarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
This is a multi-center, open-label, single-arm, phase I/II study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of mitoxantrone hydrochloride liposome injection in subjects with acute myeloid leukemia (AML).
- Trial name
- NCT05345938
- Testing
- Mitoxantrone Hydrochloride Liposome
- Where
- China
- Volunteers
- 1 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Multiple Sclerosis
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).
- Trial name
- SUNBEAM (NCT02294058)
- Testing
- Ozanimod, Interferon beta-1a
- Where
- 224 sites in United States, Belarus and 23 more
- Volunteers
- 1,346 people
- Sponsor
- Celgene
Lymphoma, Non-Hodgkin
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
The purpose of this study is to assess whether copanlisib in combination with standard immunochemotherapy (rituximab in combination with bendamustine [R-B] and rituximab in combination with a 4 drug combination of…
- Trial name
- CHRONOS-4 (NCT02626455)
- Testing
- Copanlisib (BAY80-6946), Rituximab, Cyclophosphamide
- Where
- 201 sites in United States, Australia and 33 more
- Volunteers
- 551 people
- Sponsor
- Bayer
Lymphoma, Non-Hodgkin
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy.
- Trial name
- NCT05824585
- Testing
- DZD8586
- Where
- 5 sites in United States, Australia
- Volunteers
- 17 people
- Sponsor
- Dizal Pharmaceuticals
Colorectal Cancer
NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of NB1011 in treating patients who have metastatic or…
- Trial name
- NCT00031616
- Testing
- brivudine phosphoramidate
- Where
- 2 sites in United States
- Sponsor
- NewBiotics
Relapsed and/or Refractory Multiple Myeloma
Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to determine the safety and tolerability of elotuzumab administered in combination with thalidomide and dexamethasone in the treatment of relapsed and/or refractory multiple myeloma.
- Trial name
- NCT01632150
- Testing
- Elotuzumab, Thalidomide, Dexamethasone
- Where
- 10 sites in Spain
- Volunteers
- 51 people
- Sponsor
- Bristol-Myers Squibb
Myeloid Leukemia
Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia
The purpose of this study is to assess safety and tolerability of multiple ascending doses of AZD1152 and to assess effect of AZD1152 on the rate of complete remission in patients with relapsed acute myeloid leukaemia.
- Trial name
- NCT00497991
- Testing
- AZD1152
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Relapsing Multiple Sclerosis (RMS)
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).
- Trial name
- NCT04130997
- Testing
- Ublituximab
- Where
- 86 sites in United States, Belarus and 6 more
- Volunteers
- 1,100 people
- Sponsor
- TG Therapeutics, Inc.
Leukemia, Myeloid, Acute
Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
The purpose of this study is to characterize the safety and tolerability of JNJ-63709178 and identify the recommended Phase 2 dose(s) (RP2D) and schedule for JNJ-63709178 in Part 1 and to characterize the safety and tolerability…
- Trial name
- NCT02715011
- Testing
- JNJ-63709178
- Where
- 10 sites in United States, Spain
- Volunteers
- 62 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma
- Trial name
- NCT05238311
- Testing
- Elranatamab
- Sponsor
- Pfizer
Acute Leukemia
A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
A phase I-II open label study of PTX-200 in combination with cytarabine in the treatment of relapsed or refractory acute leukemia.
- Trial name
- NCT02930109
- Testing
- PTX-200, Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Prescient Therapeutics, Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.